JP2025111457A5 - - Google Patents

Info

Publication number
JP2025111457A5
JP2025111457A5 JP2025052993A JP2025052993A JP2025111457A5 JP 2025111457 A5 JP2025111457 A5 JP 2025111457A5 JP 2025052993 A JP2025052993 A JP 2025052993A JP 2025052993 A JP2025052993 A JP 2025052993A JP 2025111457 A5 JP2025111457 A5 JP 2025111457A5
Authority
JP
Japan
Prior art keywords
sequence
seq
spik
antibody
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025052993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025111457A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/041228 external-priority patent/WO2021007338A1/en
Application filed filed Critical
Publication of JP2025111457A publication Critical patent/JP2025111457A/ja
Publication of JP2025111457A5 publication Critical patent/JP2025111457A5/ja
Pending legal-status Critical Current

Links

JP2025052993A 2019-07-08 2025-03-27 カザール型抗セリンプロテアーゼ阻害因子(spik)抗体、免疫複合体、及び使用方法 Pending JP2025111457A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962871565P 2019-07-08 2019-07-08
US62/871,565 2019-07-08
PCT/US2020/041228 WO2021007338A1 (en) 2019-07-08 2020-07-08 Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
JP2022500004A JP7658946B2 (ja) 2019-07-08 2020-07-08 カザール型抗セリンプロテアーゼ阻害因子(spik)抗体、免疫複合体、及び使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022500004A Division JP7658946B2 (ja) 2019-07-08 2020-07-08 カザール型抗セリンプロテアーゼ阻害因子(spik)抗体、免疫複合体、及び使用方法

Publications (2)

Publication Number Publication Date
JP2025111457A JP2025111457A (ja) 2025-07-30
JP2025111457A5 true JP2025111457A5 (https=) 2025-10-30

Family

ID=71944318

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022500004A Active JP7658946B2 (ja) 2019-07-08 2020-07-08 カザール型抗セリンプロテアーゼ阻害因子(spik)抗体、免疫複合体、及び使用方法
JP2025052993A Pending JP2025111457A (ja) 2019-07-08 2025-03-27 カザール型抗セリンプロテアーゼ阻害因子(spik)抗体、免疫複合体、及び使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022500004A Active JP7658946B2 (ja) 2019-07-08 2020-07-08 カザール型抗セリンプロテアーゼ阻害因子(spik)抗体、免疫複合体、及び使用方法

Country Status (6)

Country Link
US (1) US12377162B2 (https=)
EP (1) EP3996816A1 (https=)
JP (2) JP7658946B2 (https=)
CN (2) CN114174341A (https=)
CA (1) CA3145301A1 (https=)
WO (1) WO2021007338A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112292401A (zh) 2018-03-06 2021-01-29 英凯尔生物科技有限责任公司 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
EP3996816A1 (en) 2019-07-08 2022-05-18 Imcare Biotech, LLC Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
WO2021050217A1 (en) * 2019-09-11 2021-03-18 Imcare Biotech, Llc. Epitopes of anti-serine protease inhibitor kazal (spik) antibodies
US20250369960A1 (en) * 2022-06-30 2025-12-04 Allonnia, Llc Per- and polyfluorinated alkyl compound (pfas) binding proteins and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
KR100332254B1 (ko) 1993-10-01 2002-09-27 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 신규인펩티드유도체
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
AU2003294210A1 (en) 2002-07-31 2004-05-04 Seattle Genetics, Inc Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
WO2007030560A2 (en) 2005-09-08 2007-03-15 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
CA2703140A1 (en) 2007-10-25 2009-04-30 Viventia Biotech Inc. Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof
MX2011010265A (es) 2009-04-01 2011-10-11 Genentech Inc Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
US20110206697A1 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Spink1 targeted therapy
US20140308657A1 (en) * 2010-12-09 2014-10-16 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Serine protease inhibitor kazal antibodies
CN105968209B (zh) 2011-04-19 2021-08-03 美国政府(由卫生和人类服务部的部长所代表) 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途
WO2014127200A1 (en) 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
WO2015164757A1 (en) 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EP4219559A3 (en) 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antibodies for lilrb2
CN112292401A (zh) 2018-03-06 2021-01-29 英凯尔生物科技有限责任公司 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
CN109678950B (zh) 2019-01-08 2022-05-10 灏灵赛奥(天津)生物科技有限公司 spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品
EP3996816A1 (en) 2019-07-08 2022-05-18 Imcare Biotech, LLC Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
WO2021050217A1 (en) * 2019-09-11 2021-03-18 Imcare Biotech, Llc. Epitopes of anti-serine protease inhibitor kazal (spik) antibodies
MX2022012752A (es) 2020-04-15 2023-01-16 Voyager Therapeutics Inc Compuestos de union a tau.

Similar Documents

Publication Publication Date Title
JP2025111457A5 (https=)
JP2023071956A5 (https=)
JP2020526478A5 (https=)
JP2009541204A5 (https=)
RU2010117018A (ru) Антитела к gdf8 и их применения
JP2007527406A5 (https=)
JP6081699B2 (ja) Il−28bの分析方法
JP2016500659A5 (https=)
JP2020516603A5 (https=)
JP2018525320A5 (https=)
JP2012511026A5 (https=)
JP2018515071A5 (https=)
JP2021501579A5 (https=)
JP2018501483A (ja) 干渉を減少させるための方法
JP2021515597A5 (https=)
JP2020189843A5 (https=)
JPWO2020190737A5 (https=)
WO2004081569A1 (ja) 腫瘍マーカーとしてのn1,n12-ジアセチルスペルミン
RU2019132201A (ru) Антитела к человеческому эритроферрону и их применение
JP2021155416A5 (https=)
JP2019138777A5 (https=)
JPWO2021007338A5 (https=)
EP4189396A1 (en) Improved epitope for detecting and/or quantifying autoantibodies against alpha-fetoprotein
US20240118278A1 (en) Hbv diagnostic, prognostic, and therapeutic methods and products
JP2018524270A5 (https=)